Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | POLE P286R |
Therapy | Nivolumab |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
POLE P286R | colorectal cancer | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a Phase II trial, Opdivo (nivolumab) resulted in a complete response in a colorectal cancer patient harboring POLE P286R, along with high tumor mutational burden and CD8-positive high tumor infiltrating lymphocytes, and a partial response in a different colorectal cancer patient also harboring POLE P286R, along with high tumor mutational burden (PMID: 35398880; NCT03012581). | 35398880 |
POLE P286R | colorectal cancer | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a retrospective study, treatment with immune checkpoint inhibitors resulted in an overall response rate of 89% (22/29) and a disease control rate of 92% in metastatic colorectal cancer patients harboring pathogenic POLE/POLD1 variants, including a complete response in a patient harboring POLE P286R treated with Opdivo (nivolumab) (PMID: 38777726). | 38777726 |
PubMed Id | Reference Title | Details |
---|---|---|
(35398880) | PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. | Full reference... |
(38777726) | Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. | Full reference... |